

Ummusen Kaya Akca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9576531/publications.pdf>

Version: 2024-02-01

25
papers

296
citations

1039406

9
h-index

996533

15
g-index

27
all docs

27
docs citations

27
times ranked

437
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on “Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine-learning-based model to assist the diagnosis of systemic lupus erythematosus”™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e144-e144.	0.5	5
2	Comparison of IVIG resistance predictive models in Kawasaki disease. <i>Pediatric Research</i> , 2022, 91, 621-626.	1.1	16
3	IgG4-related disease in pediatric patients: a single-center experience. <i>Rheumatology International</i> , 2022, 42, 1177-1185.	1.5	10
4	The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. <i>Rheumatology International</i> , 2022, 42, 469-475.	1.5	16
5	Impact of the COVID-19 pandemic on the frequency of the pediatric rheumatic diseases. <i>Rheumatology International</i> , 2022, 42, 51-57.	1.5	13
6	Challenges in diagnosing COVID-19 related disease in pediatric patients with rheumatic disease. <i>Modern Rheumatology</i> , 2022, 32, 1108-1113.	0.9	4
7	The performances of the ILAR, ASAS, and PRINTO classification criteria in ERA patients: a comparison study. <i>Clinical Rheumatology</i> , 2022, 41, 1785-1792.	1.0	5
8	Probiotic use in the prophylaxis of periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) syndrome: a retrospective cohort study. <i>Rheumatology International</i> , 2022, , 1.	1.5	7
9	The difference of the inflammatory milieu in MIS-C and severe COVID-19. <i>Pediatric Research</i> , 2022, 92, 1805-1814.	1.1	24
10	Treatment of childhood-onset Takayasu arteritis: switching between anti-TNF and anti-IL-6 agents. <i>Rheumatology</i> , 2022, 61, 4885-4891.	0.9	4
11	The challenges in diagnosing pediatric primary antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 1269-1275.	0.8	4
12	The Performances of the ACR 1997, SLICC 2012, and EULAR/ACR 2019 Classification Criteria in Pediatric Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 907-914.	1.0	28
13	Performances of the “MS-score” And “HScore” in the diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis patients. <i>Rheumatology International</i> , 2021, 41, 87-93.	1.5	3
14	Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean. <i>Clinical Rheumatology</i> , 2021, 40, 3227-3237.	1.0	29
15	SIMILARITIES AND DIFFERENCES BETWEEN FAMILIAL MEDITERRANEAN FEVER AND BEHÇET’S DISEASE. <i>Central Asian Journal of Medical Hypotheses and Ethics</i> , 2021, 2, 43-50.	0.2	2
16	Systematic review of childhood-onset polyarteritis nodosa and DADA2. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 559-564.	1.6	14
17	Real-world data on MTX tolerance with regimens used in children versus adults. <i>Clinical Rheumatology</i> , 2021, 40, 5095-5102.	1.0	2
18	Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study. <i>Lupus</i> , 2021, 30, 1983-1990.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 32-38.	0.4	3
20	Is Takayasu's arteritis more severe in children?. Clinical and Experimental Rheumatology, 2021, 39, 32-38.	0.4	16
21	Kawasaki-like disease in children with COVID-19. Rheumatology International, 2020, 40, 2105-2115.	1.5	67
22	Comorbidities of antiphospholipid syndrome and systemic lupus erythematosus in children. Current Rheumatology Reports, 2020, 22, 21.	2.1	4
23	The Challenge of Treating Pulmonary Vasculitis in Behçet Disease: Two Pediatric Cases. Pediatrics, 2019, 144, .	1.0	9
24	AB0993â€¦COMORBIDITIES IN FAMILIAL MEDITERRANEAN FEVER. , 2019, , .		1
25	The performance of IgG4-related disease responder index in children. Clinical and Experimental Rheumatology, 0, , .	0.4	0